← Back to headlines
Connext Completes Enrollment in Phase 2 Trial for Dupuytren's Contracture Drug
Connext has announced the successful completion of patient enrollment for its Phase 2 clinical trial of CNT201, a drug designed to treat Dupuytren's Contracture.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
